IGFBP2 and esophageal cancer: This indicates that changes in IGFBP-2 expression levels are related to changes in the condition of patients with esophageal cancer, and the significant decrease in IGFBP-2 test values in patients with esophageal cancer after combination therapy reflects that combination therapy can achieve significant therapeutic effects, and has a positive impact on controlling the development and improving the condition of patients with esophageal cancer.